Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hpv e7 antigen-loaded autologous dendritic cells
- Development stage
- Unknown
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A **personalized cellular immunotherapy** consisting of **autologous dendritic cells (DC)** derived from a patient's peripheral blood, ex vivo loaded (pulsed) with recombinant human papillomavirus (HPV) E7 oncoprotein (typically from HPV16 and/or HPV18 genotypes), and then administered as a therapeutic vaccine to stimulate antigen-specific cytotoxic and helper T-cell responses against HPV-infected tumor cells. The approach targets the immune system to specifically recognize and eliminate cervical cancer cells expressing the HPV E7 oncogene. Administration has shown to be safe and immunogenic, primarily inducing CD4+ and CD8+ T-cell responses, with delayed-type hypersensitivity observed in treated patients. The vaccine is investigational, under development primarily for cervical cancer at high risk of recurrence following surgery[1][3].
- Brand names
- HPV16/18 E7-pulsed dendritic cells
- Other names
- HPV16/18 E7-pulsed dendritic cellsHPV E7-loaded DC vaccineE7 antigen-pulsed autologous dendritic cellsE-7 antigen-pulsed autologous dendritic cellsE 7 antigen-pulsed autologous dendritic cells
02
Targets
E7 (Papillomavirus E6/E7 oncoproteins)HPV16 E7 TCR (HPV16 E7-specific T-cell receptor)LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on hpv e7 antigen-loaded autologous dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hpv e7 antigen-loaded autologous dendritic cells.